Cancer BiologybioRxivPreprint
Targeting CD19-positive lymphomas with the antibody-drug conjugate (ADC) loncastuximab tesirine: preclinical evidence as single agent and as combinatorial approach
C. Tarantelli, D. Wald, N. Munz…·F. Bertoni
This study evaluates the efficacy of the anti-CD19 ADC loncastuximab tesirine as a single agent and in combination with other therapies against lymphomas.
DOI 10.1101/2023.08.17.553668